Stock comparison
IRadimed
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IRMD
IRadimed
Market cap
$1.18B
Sector
Healthcare
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
Overall winner
IRadimed IRMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IRMD | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 68B | 72B | RMD |
| Benjamin Graham | 89A | 75B | IRMD |
| Philip Fisher | 92A | 75B | IRMD |
| Peter Lynch | 76B | 58C | IRMD |
| Joel Greenblatt | 65C | 47D | IRMD |
| Charlie Munger | 78B | 69B | IRMD |
| Terry Smith | 75B | 73B | IRMD |
Side-by-side metrics
| Metric | IRMD | RMD |
|---|---|---|
| Market cap | $1.18B | $30.18B |
| P/E (TTM) | 50.4x | 19.6x |
| EV/EBIT | 43.4x | 17.1x |
| ROIC (TTM) | 21.38% | 19.63% |
| Gross margin | 76.84% | 61.69% |
| Net margin | 27.36% | 27.44% |
| Revenue CAGR 5y | 18.99% | 12.64% |
| EPS CAGR 5y | 23.53% | 30.73% |
| Debt / Equity | - | 0.1x |
| Dividend yield | 1.33% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IRMD leads on
- Debt / Equity-vs 0.1x+100%
- Revenue CAGR 5y18.99%vs 12.64%+33%
- Gross margin76.84%vs 61.69%+20%
- Dividend yield1.33%vs 1.14%+14%
RMD leads on
- Market cap$30.18Bvs $1.18B+96%
- P/E (TTM)19.6xvs 50.4x+61%
- EV/EBIT17.1xvs 43.4x+61%
- EPS CAGR 5y30.73%vs 23.53%+23%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.